CRISPR's New Gig: Slaying a Bottleneck in Genomic Sequencing

BOULDER, CO – February 17, 2026 – In a move that highlights the expanding utility of CRISPR technology, Watchmaker Genomics has secured a license to use the famed gene-editing tool for a purpose far removed from altering DNA: to fix one of the most persistent and costly bottlenecks in modern life sciences.

The Boulder-based innovator in next-generation sequencing (NGS) solutions announced a non-exclusive license agreement with Caribou Biosciences for its foundational CRISPR-Cas9 intellectual property. Rather than editing genes, Watchmaker is deploying CRISPR as a highly precise molecular clamp, aiming to revolutionize library normalization—a critical but notoriously cumbersome step in preparing samples for sequencing. This novel approach promises to increase throughput, reduce costs, and improve data quality for labs on the front lines of genomic research and clinical diagnostics.

“Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founder at Watchmaker Genomics, in the company's announcement. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequencing needs.”

Beyond Editing: CRISPR's New Role in the Lab

When most people hear "CRISPR," they think of its revolutionary ability to act like molecular scissors, precisely cutting and pasting DNA to correct genetic defects. But its core function—the ability to find a specific DNA sequence with unparalleled accuracy—is what Watchmaker Genomics is harnessing. The company is using a catalytically inactive or "dead" version of the Cas9 protein (dCas9), which can be programmed to find and bind to a target sequence without making a cut.

In this application, the CRISPR-dCas9 complex is guided to the universal adapter sequences that are attached to every DNA fragment in a sequencing-ready library. By adding a predetermined, or stoichiometric, amount of this binding agent to a batch of different libraries, the system effectively grabs an equal number of molecules from each sample. This elegantly achieves equimolar pooling without the need for individual quantification and dilution.

This method is a stark departure from traditional techniques. For decades, labs have relied on laborious processes like qPCR or fluorometry to measure the concentration of each library one by one. Technicians then perform manual calculations and painstaking pipetting to dilute each sample to a uniform concentration before pooling them for sequencing. The process is not only a major time sink but also a significant source of error and variability, with typical read depth variations ranging from 10-25% across samples in a pool.

Watchmaker's CRISPR-based approach is non-destructive, meaning the DNA libraries are not damaged or altered, preserving their complexity and integrity for potential re-sequencing or other downstream applications. Furthermore, it is designed to slot directly into existing lab workflows without requiring specialized new instrumentation, a key factor for accelerating adoption.

Solving the Sequencing Bottleneck

The challenge of library normalization has long been an open secret in the genomics world. As sequencing machines have become exponentially more powerful, capable of processing billions of DNA strands in a single run, the preparatory steps have struggled to keep pace. This mismatch has created a significant workflow bottleneck that inflates costs and timelines.

Inaccurate normalization leads to wasted resources. If some libraries in a pool are over-concentrated, they dominate the sequencing run, consuming expensive reagents and generating redundant data while "starving" the under-concentrated libraries of reads. This often forces labs to re-sequence entire batches, doubling costs and delaying results. The manual nature of traditional normalization also makes it difficult to integrate into the highly automated, high-throughput environments common in modern genomics facilities.

By eliminating the need for discrete quantification, Watchmaker's technology directly addresses these pain points. The approach is designed for automation, enabling labs to process more samples with greater predictability and less hands-on time.

“The goal isn’t just to make normalization faster,” Kudlow noted. “It’s to make it more predictable and more compatible with the way sequencing is actually done today: at scale, under automation, and across diverse sample types.”

This innovation enters a competitive but rapidly growing market. The global NGS library preparation market was valued at over $1.4 billion in 2023 and is projected to approach $5 billion by 2033. While industry giants like Illumina, Thermo Fisher Scientific, and New England Biolabs offer their own solutions, including enzymatic and magnetic bead-based normalization kits, Watchmaker's patented use of CRISPR as a programmable binding tool offers a unique mechanism that could provide a new level of precision and workflow simplicity.

A Strategic Play in a Competitive Market

The licensing deal is a savvy strategic move for Watchmaker Genomics, arming it with a differentiated technology in a crowded field. By securing rights to Caribou's foundational IP and combining it with its own recently issued patent for the method, the company has carved out a defensible niche. This strategy of repurposing a breakthrough technology for a workflow-level innovation could become a significant growth driver.

For Caribou Biosciences, a clinical-stage biopharmaceutical company focused on developing its own CRISPR-based therapies, the agreement fits a well-established pattern of out-licensing its powerful IP for non-therapeutic applications. This approach allows Caribou to generate revenue while enabling broader innovation across the life sciences ecosystem, from agriculture to research tools.

This new technology is poised to have its most significant impact on large-scale sequencing initiatives, where efficiency and cost-effectiveness are paramount. By streamlining a key bottleneck, Watchmaker is enabling researchers to ask bigger questions and analyze more samples, accelerating the pace of discovery in population genomics, oncology, and beyond.

Powering the Future of Whole Genome Sequencing

Watchmaker is specifically adapting this CRISPR-enabled strategy as a cornerstone of a complete solution for PCR-free whole genome sequencing (WGS). PCR-free methods are the gold standard for WGS because they avoid the amplification step, which can introduce biases and errors into the final sequence data. However, forgoing amplification means the initial library preparation must be exceptionally efficient to generate enough material for sequencing.

The precision of CRISPR-based normalization is particularly beneficial here. It ensures that precious, non-amplified libraries are pooled with high accuracy, maximizing data quality and minimizing the need for high DNA input amounts. This is critical for applications like newborn screening or rare disease diagnostics, where patient samples may be scarce. By improving sequencing efficiency and simplifying operations for PCR-free WGS, the technology can help make high-quality genomic analysis more accessible and affordable for clinical applications.

As genomics continues its march from the research lab into mainstream medicine, such fundamental workflow innovations will be just as crucial as the sequencers themselves. By creatively applying a Nobel Prize-winning technology to solve a practical, long-standing problem, Watchmaker Genomics is helping to pave the way for a future where high-quality genomic information is more readily available to drive scientific discovery and improve human health.